News

The Pulmonary Hypertension Association (PHA) is calling on people affected by pulmonary hypertension (PH) to attend the free PHA on the Road: PH Patients and Families Education Forum it is helping to sponsor on Nov. 1, at the Marriott Waterside Hotel & Marina in Tampa, Florida. Carolyn Sheehy…

Mast Therapeutics announced that positive interim data from its ongoing Phase 2a clinical trial of AIR001 (sodium nitrite, or Aironite) inhalation solution for the treatment of patients with pulmonary hypertension (PH) have been published in the Journal of Clinical Investigation (JCI). The open label, Phase 2a clinical trial (NCT01431313) is evaluating…

How people with pulmonary arterial hypertension (PAH) are diagnosed and treated depends to a notable degree on the country or region in which they live, according to a new study, which also found that a sizable number never undergo right heart catheterization to confirm their disease. The findings, published in the…

The Pulmonary Hypertension Association (PHA) has started a social media video campaign, A Heart Cures, asking people to make and share 10- to 30-second videos of themselves giving thanks to loved ones or strangers for little acts of kindness and support. Posted videos will run through November, which is both…

Results from a Phase 3 study showed that treating pulmonary arterial hypertension (PAH) patients with oral Opsumit (macitentan) improved both their physical and mental health, positively impacting their quality of life (QoL). PAH is a progressive disease characterized by the difficulty to breathe and recurrent fatigue.  Several studies have shown that PAH affects a person’s mental…

Inhalation treatment that uses either nitric oxide or Ventavis (iloprost) is equally effective in managing lingering high lung blood pressure after surgery for chronic thromboembolic pulmonary hypertension (CTEPH). A comparison of the two treatments — published in the journal General Thoracic and Cardiovascular Surgery under the title, “A prospective, randomized study…

Although subcutaneous infusion of Remodulin (treprostinil) is an effective treatment for patients with severe pulmonary arterial hypertension (PAH), it can have undesired effects such as pain at the infusion site. But a study reports that speeding up Remodulin administration, and combining it with injection-site pain management, is an easily tolerated option that may help patients better…

Gilead Sciences reported that selonsertib (also known as GS-4997), an investigational treatment for pulmonary arterial hypertension (PAH), did not achieve the primary endpoint in an analysis of ARROW, a Phase 2 clinical trial (NCT02234141) evaluating the drug’s efficacy, safety and tolerability. The company also reported top-line data from two other…

A team of researchers at Columbia University Medical Center and New York Presbyterian Hospital advise patients with pulmonary hypertension no to become pregnant, based on the case of a 28-year-old woman who was diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH), or group 4 pulmonary hypertension, during her pregnancy.

Pregnancy can be a trigger for pulmonary arterial hypertension (PAH) in women with a genetic predisposition to the disease, according to a case study published in the journal Pulmonary Circulation. In the study, “Pregnancy As A Possible Trigger For Heritable Pulmonary Arterial Hypertension,” researchers detail the development of aggressive PAH during…

For the first time, people affected by a host of different diseases, mainly conditions affecting the heart, lungs, kidneys, and liver, met with members of the European parliament to brainstorm ways to efficiently solve issues regarding organ donation and transplant. Healthcare experts, patients, and their families were at the Oct. 18 meeting,…

Bayer will present new data from two different studies of Adempas (riociguat) for pulmonary arterial hypertension (PAH) at the American College of Chest Physicians (CHEST) 2016 Annual Meeting Oct. 22-26 in Los Angeles. One of the presentations will be held during the Late-Breaking Abstracts session of the meeting. Bayer will also…